Invest Europe recognised as key reference point in European Biotech Act I

In its Staff Working Document (published on 26 May), an analytical and explanatory document that sits alongside and supporting the European Biotech Act I legislative proposal, the European Commission's arm responsible for implementing EU laws on public health, food safety, and animal and plant welfare (DG SANTE) uses “venture capital investment flows in biotechnology in the Union” as a key success indicator, explicitly citing Invest Europe Annual Activity Statistics as the source to assess this indicator.

This means that the European Commission will rely on Invest Europe's data to assess the success - the implementation, effectiveness and overall impact - of the Biotech Act I from an access-to-finance perspective, making it the key benchmark in this area. Notably, this is the only indicator used to assess financing under the Act.

This is a significant signal:

It confirms that private capital mobilisation is seen by policymakers as a central driver of success for Europe’s biotechnology strategy.
It underscores Invest Europe’s role as the trusted reference point for data on private capital investment in the sector.

This recognition reflects the consistency, credibility and robustness of our industry-led data, as well as its direct relevance for EU policymaking. It also reinforces the analytical backbone of our policy work. The same data now used by the European Commission underpins our position papers on the Biotech Act I and on biotech and healthcare, where we set out concrete, evidence-based reforms to unlock private capital and strengthen Europe’s biotech and healthcare financing ecosystem.